Vallabh Janardhan: Vascular Disease Is Ultimately A Story of Thrombosis
Vallabh Janardhan, Co-Founder and CMO at Insera Therapeutics, Inc., shared on LinkedIn:
”Dallas CV Updates 2026 reinforced something I’ve been thinking about increasingly: vascular disease is ultimately a story of thrombosis.
From coronary plaque rupture to embolic stroke to venous thromboembolism, the final common pathway is clot biology.
A particularly compelling discussion this year centered on Lipoprotein(a) by Dr. Shahzeb Khan — not only as an atherogenic particle, but as a pro-thrombotic contributor that may amplify clot formation across vascular beds.
As our understanding deepens, prevention and intervention are no longer separate conversations.
Credit to Dr. Srini Potluri and Dr. Robert Smith for convening a forum that blends clinical excellence with forward-looking discussion at Baylor Scott and White The Heart Hospital.
Always energizing to engage with colleagues shaping the next phase of cardiovascular care in Dallas and beyond.”
Stay updated with Hemostasis Today.
-
Apr 8, 2026, 15:21Nathan Connell: Persistent Gaps in Hemophilia A Care Despite Prophylaxis
-
Apr 8, 2026, 15:16Avril Mansfield: Why Aren’t More Stroke Patients Meeting Aerobic Exercise Guidelines?
-
Apr 8, 2026, 15:06Sarah Richardson: We Need Experts, We Need Programs and We Need Accountability in Blood Disorders Community
-
Apr 8, 2026, 15:02Heghine Khachatryan: When Bleeding Appears Without a History — Think Acquired
-
Apr 8, 2026, 14:58Nominate a Bleeding Disorders Community Hero Making a Difference – NBDF
-
Apr 8, 2026, 14:56Joffrey Feriel: Comprehensive Review of Laboratory Assays for von Willebrand Factor and Associated Disorders
-
Apr 8, 2026, 14:54Husnain Ahmad: How Aortic Stenosis Can Lead to Gastrointestinal Bleeding in Heyde Syndrome
-
Apr 8, 2026, 14:51Steven Murphy: How Much Benefit Do Statins Really Provide for Cardiovascular Prevention
-
Apr 8, 2026, 14:42Joshua Muia: The Value of Collaboration and The Importance of Exchanging Ideas Across Institutions